Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

INTRODUCTION: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment setting. AXL, a member of the TYRO3, AXL, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Ryota, Fujii, Hiroyuki, Yamada, Tadaaki, Matsui, Yohei, Yaoi, Takeshi, Honda, Mizuki, Tanaka, Noriyuki, Miyagawa-Hayashino, Aya, Yoshimura, Akihiro, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kim, Young Hak, Konishi, Eiichi, Itoh, Kyoko, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329144/
https://www.ncbi.nlm.nih.gov/pubmed/37426308
http://dx.doi.org/10.1016/j.jtocrr.2023.100525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329144/
https://www.ncbi.nlm.nih.gov/pubmed/37426308
http://dx.doi.org/10.1016/j.jtocrr.2023.100525

Ejemplares similares